文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症复杂临床表现、SEP-1依从性与结局

Complex Sepsis Presentations, SEP-1 Compliance, and Outcomes.
PubMed 文献 · JAMA Netw Open · 2025-03-03
一句话结论脓毒症表现越复杂(无发热、精神状态改变、合并症多、需床旁操作),SEP-1依从性越低;校正复杂临床标志后,SEP-1依从性与住院死亡率无显著差异。

该回顾性队列研究纳入2019年1月1日至2022年12月31日4所学术医院急诊科的590例成人脓毒症患者,335例(56.8%)接受SEP-1依从性治疗,225例(43.2%)未依从。未依从组更多为≥65岁、Elixhauser评分>20、脓毒性休克、肾功能障碍、血小板减少、无发热、精神状态改变、需床旁操作、合并急性非感染性疾病及以非感染性疾病为主要表现。SEP-1依从性与较低粗死亡率相关(11.9% vs 16.1%;未校正OR 0.60 [95%CI 0.37-0.98]),但逐步校正人口学与合并症、感染源、疾病严重度及复杂临床标志后,差异均无统计学显著(最终AOR 1.08 [95%CI 0.61-1.91])。

要点

  • 590例急诊成人脓毒症中,SEP-1依从335例(56.8%),未依从225例(43.2%)。
  • 未依从组更常见无发热(53.3% vs 36.1%;OR 2.02 [95%CI 1.45-2.82])和需床旁操作(22.4% vs 12.2%;OR 2.06 [95%CI 1.33-3.21])。
  • 未依从组更多脓毒性休克(42.0% vs 31.9%;OR 1.54 [95%CI 1.10-2.16])、肾功能障碍(34.1% vs 23.9%;OR 1.65 [95%CI 1.15-2.37])。
  • SEP-1依从性与较低粗死亡率相关(11.9% vs 16.1%;未校正OR 0.60 [95%CI 0.37-0.98])。
  • 逐步校正后依从性与住院死亡率均无统计学显著差异,最终AOR 1.08(95%CI 0.61-1.91)。

适用人群与场景

  • 2019年1月1日至2022年12月31日在4所学术医院急诊科就诊的590例成人脓毒症患者。
  • 患者病历在2022年9月至2023年12月间被复核。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量590例;4所学术医院;人群为急诊科成人脓毒症患者。
  • 主要结局:SEP-1依从性(335例,56.8%) vs 未依从(225例,43.2%);未依从组与≥65岁(55.7% vs 47.2%;OR 1.41 [95%CI 1.01-1.95])、Elixhauser评分>20(38.8% vs 29.6%;OR 1.51 [95%CI 1.07-2.13])、脓毒性休克(42.0% vs 31.9%;OR 1.54 [95%CI 1.10-2.16])、肾功能障碍(34.1% vs 23.9%;OR 1.65 [95%CI 1.15-2.37])、血小板减少(16.9% vs 11.0%;OR 1.16 [95%CI 1.02-2.62])相关。
  • 未依从组更多无发热(53.3% vs 36.1%;OR 2.02 [95%CI 1.45-2.82])、精神状态改变(36.1% vs 28.1%;OR 1.45 [95%CI 1.02-2.05])、需床旁操作(22.4% vs 12.2%;OR 2.06 [95%CI 1.33-3.21])、合并急性非感染性疾病(54.9% vs 45.1%;OR 1.48 [95%CI 1.07-2.06])、以非感染性疾病为主要表现(32.9% vs 21.2%;OR 1.82 [95%CI 1.08-3.08])。
  • SEP-1依从性与较低粗死亡率相关(11.9% vs 16.1%;未校正OR 0.60 [95%CI 0.37-0.98]);校正人口学与合并症后AOR 0.71(95%CI 0.42-1.18),校正感染源后AOR 0.71(95%CI 0.43-1.20),校正疾病严重度后AOR 0.86(95%CI 0.50-1.49),校正复杂临床标志后AOR 1.08(95%CI 0.61-1.91)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示,无发热、精神状态改变、多种合并症、脓毒性休克、肾功能障碍、血小板减少、需床旁操作及以非感染性疾病为主要表现等复杂临床情况在SEP-1未依从患者中更常见。
  • 该研究提示,这些复杂临床特征在多数观察性研究中未被充分捕捉,并混杂了SEP-1依从性与死亡率之间的关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The Centers for Medicare & Medicaid Services Severe Sepsis and Septic Shock Management Bundle (SEP-1) is supported by observational studies that report SEP-1 compliance is associated with lower mortality. Most studies, however, adjusted for limited confounders and provided little insight into why bundle-compliant care was not provided.

OBJECTIVES: To identify the clinical factors that complicate the diagnosis and management of sepsis and assess their association with SEP-1 compliance and mortality.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted among 590 adults with sepsis in the emergency department of 4 academic hospitals from January 1, 2019, to December 31, 2022. Patients' medical records were reviewed between September 2022 and December 2023.

MAIN OUTCOMES AND MEASURES: Study outcomes were (1) characteristics of patients who received SEP-1-compliant care vs characteristics of patients who received noncompliant care and (2) association between SEP-1 compliance and hospital mortality using multivariable models to adjust for successively more potential confounders (first demographics and comorbidities, then infection source, then severity of illness, and then clinical markers of complexity).

RESULTS: Of 590 patients with sepsis (median age, 65 years [IQR, 53-77 years]; 329 men [55.8%]), 335 (56.8%) received SEP-1-compliant care, and 225 (43.2%) received noncompliant care. Compared with patients in the compliant group, patients in the noncompliant group were more likely to be 65 years or older (142 [55.7%] vs 158 [47.2%]; odds ratio [OR], 1.41 [95% CI, 1.01-1.95]), to have multiple comorbidities (Elixhauser score >20: 99 [38.8%] vs 99 [29.6%]; OR, 1.51 [95% CI, 1.07-2.13]), and to have a higher incidence of septic shock (107 [42.0%] vs 107 [31.9%]; OR, 1.54 [95% CI, 1.10-2.16]), kidney dysfunction (87 [34.1%] vs 80 [23.9%]; OR, 1.65 [95% CI, 1.15-2.37]), and thrombocytopenia (43 [16.9%] vs 37 [11.0%]; OR, 1.16 [95% CI, 1.02-2.62]) on presentation. Compared with patients in the compliant group, those in the noncompliant group also had more nonfebrile presentations (136 [53.3%] vs 121 [36.1%]; OR, 2.02 [95% CI, 1.45-2.82]), impaired mental status (92 [36.1%] vs 94 [28.1%]; OR, 1.45 [95% CI, 1.02-2.05]), need for bedside procedures (57 [22.4%] vs 41 [12.2%]; OR, 2.06 [95% CI, 1.33-3.21]), acute concurrent noninfectious illnesses (140 [54.9%] vs 151 [45.1%]; OR, 1.48 [95% CI, 1.07-2.06]), and noninfectious illness as the primary factor associated with their presentation (84 [32.9%] vs 71 [21.2%]; OR, 1.82 [95% CI, 1.08-3.08]). SEP-1 compliance was associated with lower crude mortality rates compared with noncompliance (40 [11.9%] vs 41 [16.1%]; unadjusted OR, 0.60 [95% CI, 0.37-0.98]), but there was no statistically significant difference between groups after successively adjusting for demographics and comorbidities (adjusted OR [AOR], 0.71 [95% CI, 0.42-1.18]), infection source (AOR, 0.71 [95% CI, 0.43-1.20]), severity of illness (AOR, 0.86 [95% CI, 0.50-1.49]), and clinical markers of complexity (AOR, 1.08 [95% CI, 0.61-1.91]).

CONCLUSIONS AND RELEVANCE: In this cohort study of adults with sepsis, complex clinical presentations were more common among patients whose treatment was noncompliant with SEP-1. These nuances are poorly captured in most observational studies but confound the association between SEP-1 compliance and mortality.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Rhee C, Train SE, Filbin MR, et al. Complex Sepsis Presentations, SEP-1 Compliance, and Outcomes. JAMA Netw Open. 2025. PMID: 40105841. doi:10.1001/jamanetworkopen.2025.1100

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。